Zoetis
ZTS
Market cap $73.3B

164.33 USD

-4.49

2.66%

At close Jun 13, 4:00 PM EDT

After hours

164.67

+0.34

0.21%

1 day

-2.66%

5 days

-2.66%

1 month

2.44%

3 months

2.67%

6 months

-7.77%

Year to date

1.06%

1 year

-4.08%

5 years

23.28%

10 years

233.53%

About: Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Employees: 13,800

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

126% more call options, than puts

Call options by funds: $384M | Put options by funds: $170M

34% more first-time investments, than exits

New positions opened: 164 | Existing positions closed: 122

8% more funds holding in top 10

Funds holding in top 10: 13 [Q4 2024] → 14 (+1) [Q1 2025]

4% more repeat investments, than reductions

Existing positions increased: 739 | Existing positions reduced: 713

0% more funds holding

Funds holding: 1,838 [Q4 2024] → 1,839 (+1) [Q1 2025]

1% less capital invested

Capital invested by funds: $67.9B [Q4 2024] → $67.5B (-$459M) [Q1 2025]

0.84% less ownership

Funds ownership: 92.43% [Q4 2024] → 91.59% (-0.84%) [Q1 2025]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$165

0%

upside

Avg. target

$182

11%

upside

High target

$210

28%

upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

Piper Sandler David Westenberg	28%upside $210	Overweight Maintained	12 May 2025
UBS Andrea Alfonso	3%upside $170	Neutral Maintained	7 May 2025
Stifel Jonathan Block	0%upside $165	Buy Maintained	14 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 20 articles about ZTS published over the past 30 days

Zacks Investment Research

Zoetis (ZTS) Surpasses Market Returns: Some Facts Worth Knowing

Zoetis (ZTS) reached $168.82 at the closing of the latest trading day, reflecting a +1.5% change compared to its last close.

Zoetis (ZTS) Surpasses Market Returns: Some Facts Worth Knowing

Zacks Investment Research

Why Zoetis (ZTS) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Zoetis (ZTS) is a Top Growth Stock for the Long-Term

The Motley Fool

5 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off

Volatility is a part of life for long-term investors. The reasons the market goes up or down change, but the constant is that high-quality stocks, businesses that increasingly make more money over time, will reward investors if you wait long enough.

5 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off

Zacks Investment Research

Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio?

ZTS jumps 13% in a month as strong new product sales, strategic deals, and rising earnings estimates boost investor confidence.

Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio?

Zacks Investment Research

Why Is Zoetis (ZTS) Up 8.1% Since Last Earnings Report?

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock?

Why Is Zoetis (ZTS) Up 8.1% Since Last Earnings Report?

Zoetis Releases 2024 Sustainability Progress Update

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis published its 2024 Sustainability Progress Update “Advancing Sustainability in Animal Health for a Better Future” to highlight the company's continued progress toward achieving its Driven to Care aspirations. The publication represents Zoetis' fifth year reporting on its purpose-driven actions across three pillars – Communities, Animals and the Planet – that strengthen its business by creating long-term value, enhancing stakeholder trust, and supporting.

Zoetis Releases 2024 Sustainability Progress Update

The Motley Fool

2 Recession-Proof Stocks to Buy and Hold

President Trump's trade policies are sparking concerns about a potential recession. Though it's hard to predict an upcoming economic downturn, it's never a bad idea for investors to buy shares of companies that can perform relatively well even in bad times.

2 Recession-Proof Stocks to Buy and Hold

Zacks Investment Research

DSNKY vs. ZTS: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Drugs stocks have likely encountered both Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY) and Zoetis (ZTS).

DSNKY vs. ZTS: Which Stock Is the Better Value Option?

24/7 Wall Street

The “English Warren Buffett” Dumped Most of His Portfolio, But Bought Big Into These 3 Stocks

His concentrated portfolio strategy, focusing on high-quality, long-term holdings, reflects a disciplined, tech-heavy investment approach.

The “English Warren Buffett” Dumped Most of His Portfolio, But Bought Big Into These 3 Stocks

Zoetis Inc. (ZTS) William Blair 45th Annual Growth Stock Conference (Transcript)

Zoetis Inc. (NYSE:ZTS ) William Blair 45th Annual Growth Stock Conference June 3, 2025 11:40 AM ET Company Participants Wetteny Joseph - CFO Conference Call Participants Brandon Vazquez - William Blair Brandon Vazquez Right. Good morning, everyone.

Zoetis Inc. (ZTS) William Blair 45th Annual Growth Stock Conference (Transcript)

See News Rankings

Charts implemented using Lightweight Charts™